Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment

Circulating soluble programmed death-1 ligand (sPD-L1) is measurable in the serum of cancer patients. This study aimed to investigate the significance of sPD-L1 in cancer patients receiving immune checkpoint inhibitor therapy. Blood samples were obtained before and after immune checkpoint inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, So Yeon, Kim, Soyeon, Keam, Bhumsuk, Kim, Tae Min, Kim, Dong-Wan, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492653/
https://www.ncbi.nlm.nih.gov/pubmed/34611279
http://dx.doi.org/10.1038/s41598-021-99311-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492653/
https://www.ncbi.nlm.nih.gov/pubmed/34611279
http://dx.doi.org/10.1038/s41598-021-99311-y

Ejemplares similares